loading
Schlusskurs vom Vortag:
$7.56
Offen:
$7.52
24-Stunden-Volumen:
47,680
Relative Volume:
0.25
Marktkapitalisierung:
$162.03M
Einnahmen:
$66.59M
Nettoeinkommen (Verlust:
$-104.93M
KGV:
-1.5752
EPS:
-4.95
Netto-Cashflow:
$-96.48M
1W Leistung:
+6.52%
1M Leistung:
+31.48%
6M Leistung:
+35.60%
1J Leistung:
-40.34%
1-Tages-Spanne:
Value
$7.51
$7.825
1-Wochen-Bereich:
Value
$7.00
$7.825
52-Wochen-Spanne:
Value
$4.09
$17.23

Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile

Name
Firmenname
Enanta Pharmaceuticals Inc
Name
Telefon
617 607 0800
Name
Adresse
4 KINGSBURY AVENUE, WATERTOWN, MA
Name
Mitarbeiter
131
Name
Twitter
@EnantaPharma
Name
Nächster Verdiensttermin
2025-02-10
Name
Neueste SEC-Einreichungen
Name
ENTA's Discussions on Twitter

Vergleichen Sie ENTA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ENTA
Enanta Pharmaceuticals Inc
7.77 162.03M 66.59M -104.93M -96.48M -4.95
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
455.53 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
546.98 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.49 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
555.21 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.90 28.51B 3.81B -644.79M -669.77M -6.24

Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-08-09 Herabstufung JP Morgan Neutral → Underweight
2023-08-08 Herabstufung Jefferies Buy → Hold
2022-12-09 Eingeleitet H.C. Wainwright Buy
2022-07-06 Hochstufung Evercore ISI In-line → Outperform
2022-06-01 Hochstufung Evercore ISI Underperform → In-line
2021-10-07 Eingeleitet Jefferies Buy
2021-09-09 Eingeleitet SVB Leerink Mkt Perform
2021-01-29 Hochstufung JP Morgan Underweight → Neutral
2020-11-24 Eingeleitet Evercore ISI Underperform
2020-08-28 Fortgesetzt ROTH Capital Buy
2020-08-26 Eingeleitet Piper Sandler Overweight
2020-07-27 Hochstufung JMP Securities Mkt Perform → Mkt Outperform
2020-03-17 Hochstufung Robert W. Baird Neutral → Outperform
2019-11-22 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2019-09-26 Herabstufung JP Morgan Neutral → Underweight
2019-05-24 Eingeleitet Wolfe Research Outperform
2019-04-23 Hochstufung Berenberg Hold → Buy
2018-12-13 Eingeleitet Berenberg Hold
2018-06-06 Eingeleitet ROTH Capital Buy
2018-02-08 Herabstufung JP Morgan Overweight → Neutral
2018-01-02 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2017-11-21 Bestätigt RBC Capital Mkts Outperform
2017-09-15 Eingeleitet RBC Capital Mkts Outperform
2017-07-11 Hochstufung JMP Securities Mkt Perform → Mkt Outperform
2016-04-28 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2016-02-09 Bestätigt Barclays Underweight
2015-10-23 Herabstufung Barclays Equal Weight → Underweight
2015-10-23 Hochstufung JMP Securities Mkt Perform → Mkt Outperform
Alle ansehen

Enanta Pharmaceuticals Inc Aktie (ENTA) Neueste Nachrichten

pulisher
Jun 13, 2025

Enanta Pharmaceuticals’ SWOT analysis: stock shifts focus to immunology amid RSV progress - Investing.com

Jun 13, 2025
pulisher
Jun 12, 2025

ENTA’s Market Quandary: Decoding the Ups and Downs of 2023 - investchronicle.com

Jun 12, 2025
pulisher
Jun 11, 2025

FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED) - Benzinga

Jun 11, 2025
pulisher
Jun 11, 2025

FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED) - Benzinga

Jun 11, 2025
pulisher
Jun 11, 2025

AbbVie wins FDA nod for Mavyret label expansion (ABBV:NYSE) - Seeking Alpha

Jun 11, 2025
pulisher
Jun 11, 2025

Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approva - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus - Yahoo Finance

Jun 11, 2025
pulisher
Jun 10, 2025

(ENTA) Proactive Strategies - news.stocktradersdaily.com

Jun 10, 2025
pulisher
Jun 04, 2025

Enanta Pharmaceuticals (NASDAQ:ENTA) Given New $24.00 Price Target at JMP Securities - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Enanta Pharma (ENTA) Receives Target Price Boost from JMP Securi - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Enanta (ENTA) Price Target Raised as Key Clinical Results Antici - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Enanta (ENTA) Price Target Raised as Key Clinical Results Anticipated | ENTA Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Citizens JMP raises Enanta Pharmaceuticals stock price target to $24 By Investing.com - Investing.com UK

Jun 03, 2025
pulisher
May 27, 2025

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - BioSpace

May 27, 2025
pulisher
May 27, 2025

Enanta Pharmaceuticals to Present at the Jefferies Global Health - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference | ENTA Stock News - GuruFocus

May 27, 2025
pulisher
May 26, 2025

Enanta Pharmaceuticals discovers new 17β-HSD13 inhibitors - BioWorld MedTech

May 26, 2025
pulisher
May 24, 2025

Enanta Pharmaceuticals’ SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com Nigeria

May 24, 2025
pulisher
May 22, 2025

Enanta to present RSV drug study results at ESPID 2025 By Investing.com - Investing.com South Africa

May 22, 2025
pulisher
May 22, 2025

Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting - BioSpace

May 22, 2025
pulisher
May 22, 2025

Enanta to present RSV drug study results at ESPID 2025 - Investing.com

May 22, 2025
pulisher
May 19, 2025

(ENTA) On The My Stocks Page - news.stocktradersdaily.com

May 19, 2025
pulisher
May 18, 2025

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - simplywall.st

May 18, 2025
pulisher
May 15, 2025

Does Enanta Pharmaceuticals (ENTA) Have the Potential to Rally 189.58% as Wall Street Analysts Expect? - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance

May 15, 2025
pulisher
May 14, 2025

Citizens JMP Increases Enanta (ENTA) Price Target to $23 | ENTA Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

ENANTA PHARMACEUTICALS INC SEC 10-Q Report - TradingView

May 14, 2025
pulisher
May 14, 2025

Enanta stock price target raised to $23 by JMP - Investing.com Canada

May 14, 2025
pulisher
May 14, 2025

Enanta price target raised to $23 from $21 at Citizens JMP - TipRanks

May 14, 2025
pulisher
May 13, 2025

Enanta (ENTA) Reports Revenue Miss and Advances Drug Development Programs | ENTA Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Enanta Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks

May 13, 2025
pulisher
May 12, 2025

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025 - BioSpace

May 12, 2025
pulisher
May 12, 2025

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance

May 12, 2025
pulisher
May 12, 2025

Enanta Pharmaceuticals Reports Q2 Loss of $1.06 Per Share, Beati - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot - News-Times

May 12, 2025
pulisher
May 08, 2025

(ENTA) Trading Report - news.stocktradersdaily.com

May 08, 2025
pulisher
May 07, 2025

Enanta Pharmaceuticals, Inc. (ENTA): The Best Breakout Stock to Buy According to Analysts - MSN

May 07, 2025
pulisher
May 05, 2025

11 Best Breakout Stocks to Buy According to Analysts - Insider Monkey

May 05, 2025
pulisher
Apr 27, 2025

JMP Securities maintains Enanta stock with $21 target - MSN

Apr 27, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 23, 2025

(ENTA) Investment Report - news.stocktradersdaily.com

Apr 23, 2025
pulisher
Apr 08, 2025

Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation At Escmid Global 2025 - marketscreener.com

Apr 08, 2025
pulisher
Apr 08, 2025

Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025 - Business Wire

Apr 08, 2025
pulisher
Apr 08, 2025

Breakthrough RSV Treatment Achieves Double Success in Latest Clinical Trial - Stock Titan

Apr 08, 2025
pulisher
Apr 07, 2025

(ENTA) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

Apr 07, 2025
pulisher
Apr 05, 2025

Enanta stock hits 52-week low at $4.71 amid market challenges - Investing.com Canada

Apr 05, 2025
pulisher
Apr 04, 2025

Enanta stock hits 52-week low at $4.71 amid market challenges By Investing.com - Investing.com South Africa

Apr 04, 2025

Finanzdaten der Enanta Pharmaceuticals Inc-Aktie (ENTA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Enanta Pharmaceuticals Inc-Aktie (ENTA) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Kieffer Tara Lynn
Chief Product Strategy Officer
Dec 06 '24
Sale
8.06
2,283
18,401
29,305
Luu Brendan
Chief Business Officer
Dec 06 '24
Sale
8.06
2,283
18,401
36,047
Rottinghaus Scott T.
Chief Medical Officer
Dec 06 '24
Sale
8.06
866
6,980
17,918
Or Yat Sun
Chief Scientific Officer
Dec 06 '24
Sale
8.06
2,591
20,883
369,109
MELLETT PAUL J
Chief Fin. & Admin Officer
Dec 06 '24
Sale
8.06
2,591
20,883
91,710
Luly Jay R.
President and CEO
Dec 06 '24
Sale
8.06
5,142
41,445
801,638
Rottinghaus Scott T.
Chief Medical Officer
Jul 15 '24
Option Exercise
8.99
5,375
48,321
27,092
Rottinghaus Scott T.
Chief Medical Officer
Jul 15 '24
Sale
17.08
5,375
91,805
21,717
Rottinghaus Scott T.
Chief Medical Officer
Jul 11 '24
Sale
15.07
4,299
64,786
23,988
Rottinghaus Scott T.
Chief Medical Officer
Jul 12 '24
Sale
15.04
2,271
34,156
21,717
$21.05
price up icon 1.77%
$35.85
price down icon 0.53%
$21.32
price down icon 0.15%
$99.46
price down icon 1.19%
$108.80
price up icon 2.21%
biotechnology ONC
$246.51
price up icon 1.76%
Kapitalisierung:     |  Volumen (24h):